MET ONE particle counters have been manufactured since 1976 and so have a solid reputation for accuracy and reliability. The new MET ONE HHPC+ series of handheld air particle counters continue this proud tradition, and in addition add the latest USB and Ethernet technologies for data transfer.
Two, three and six channel versions are available and all sample at 2.83 lpm which enables ISO 14644-1 class 5 compliant 0.3 micron samples to be obtained in one minute. Applications include routine cleanroom monitoring, HEPA filter checks, cleanroom classification and visual particle trending.
The days of having to transcribe results by hand are gone for ever since the data can be transferred directly to a USB stick or via Ethernet direct to a PC. The MET ONE HHPC+ is always ready to use because the new design also includes a charging cradle that can be located directly in the cleanroom.
Designed for everyday use in cleanroom manufacturing environments the MET ONE HHPC+ features a 0.3 to 10 micron particle size range in size channels as per the industry standard ISO 14644-1 (FS 209E). The light weight (0.7kg) and large colour display (320 x 240 pixel) equipped with intuitive icon driven navigation ensure the HHPC+ is simple and fast to operate.
Contact HACH LANGE for further information or visit our website www.particle.com for full details of the new MET ONE HHPC+ handheld particle counter.
|
|
|
|
|
|
|
|
|
|
|
|
The European Commission has approved Afinitor® (everolimus) tablets* for the treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer (HR+ advanced breast cancer), in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.
Read full story >>
|
|
 |
|
|
|
|
|
 |
|
GSK announces acquisition of 79% of Human Genome Sciences shares
GlaxoSmithKline has announced the results of its initial tender offer for all outstanding shares of Human Genome Sciences for US$14.25 per share in cash, valuing HGS at approximately US$3.6 billion on an equity basis, or approximately US$3 billion net of cash and debt...
|
|
 |
|
pSivida announces ILUVIEN® marketing authorisation in Germany
pSivida Corp., announced that the Federal Ministry of Health of Germany has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
|
|
|
|
|
|
ACHEMA 2012 - Exclusive video interviews
|
|
|
 In this one hour instructional webinar we will discuss how handheld Raman reduces costs and improves efficiency, the move to mandatory 100% testing of incoming raw materials, and recent developments in handheld Raman technology.
Find out more >>
|
Conferences, events & exhibitions:
Drug Discovery & Diagnostic Development Week 2012
1 - 3 August 2012 San Francisco, CA, USA
Drug & Diagnostic Development
6 - 8 August 2012 San Francisco, CA, USA
Genomics Research Europe
4 - 5 September 2012 Frankfurt, Germany
ELRIG Drug Discovery 2012
5 - 6 September 2012 Manchester, UK
HUPO 11th Annual World Congress
9 - 12 September 2012 Boston, USA
Design Control for Medical Device Professionals
10 - 11 September 2012 Berlin, Germany
Design Validation, Verification, and Risk Analysis for Medical Device Professionals
12 - 13 September 2012 Berlin, Germany
Validation of Computer Systems
17 - 18 September 2012 Dublin, Ireland
The EU Clinical Trial Directive
17 - 18 September 2012 Dublin, Ireland
ADME, PK/TK, and Drug Metabolism in Drug Discovery and Development
17 - 19 September 2012 Dublin, Ireland
The Drug Development Process – From Discovery to Commercialisation
19 - 21 September 2012 Dublin, Ireland
11th Annual Biological Production Forum 2012
24 - 26 September 2012 Dusseldorf, Germany
|
|
|
